# Ricardo Blanco

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ricardo-blanco/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,515 |
| Field | Vasculitis and related conditions |
| h-index | 72 |
| i10-index | 358 |
| Last Known Institution | Universidad de Cantabria |
| OpenAlex ID | https://openalex.org/A5085520437 |
| ORCID iD | 0000-0003-2344-2285 |
| Works | 1,044 |

## Researcher papers

- [Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial](https://scholariq.org/papers/tofacitinib-cp-690-550-in-combination-with-methotrexate-in-patients-with-active/)
- [Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors](https://scholariq.org/papers/tofacitinib-for-psoriatic-arthritis-in-patients-with-an-inadequate-response-to/)
- [Henoch‐Schönlein purpura in adulthood and childhood. Two different expressions of the same syndrome](https://scholariq.org/papers/henoch-schonlein-purpura-in-adulthood-and-childhood-two-different-expressions-of/)
- [Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu](https://scholariq.org/papers/tocilizumab-inhibits-structural-joint-damage-in-rheumatoid-arthritis-patients/)
- [Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment](https://scholariq.org/papers/permanent-visual-loss-and-cerebrovascular-accidents-in-giant-cell-arteritis/)
- [Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis](https://scholariq.org/papers/guidance-on-noncorticosteroid-systemic-immunomodulatory-therapy-in-noninfectious/)
- [Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study](https://scholariq.org/papers/clinical-outcomes-of-hospitalised-patients-with-covid-19-and-chronic/)
- [Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3](https://scholariq.org/papers/efficacy-safety-and-tolerability-of-secukinumab-in-patients-with-active/)
- [Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial](https://scholariq.org/papers/efficacy-and-safety-of-upadacitinib-monotherapy-in-methotrexate-naive-patients/)
- [Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients](https://scholariq.org/papers/treatment-of-refractory-uveitis-with-adalimumab-a-prospective-multicenter-study/)
- [SER recommendations for the treatment of uveitis](https://scholariq.org/papers/ser-recommendations-for-the-treatment-of-uveitis/)

## Researcher topics

- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Otitis Media and Relapsing Polychondritis](https://scholariq.org/topics/otitis-media-and-relapsing-polychondritis/)
- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)

## Researcher university

- [Universidad de Cantabria](https://scholariq.org/institutions/universidad-de-cantabria/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.